

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0460US1	Application No. 10/542,044
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew David Morley et al.	
		Filing Date July 13, 2005	Group Art Unit 1626

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,258,357	11/02/1993	Muenster et al.			
	AB	5,571,810	11/05/1996	Matsuo et al.			
	AC	5,679,670	10/21/1997	Dean et al.			
	AD	6,048,880	04/11/2000	Kawai et al.			
	AE	6,380,214	04/30/2002	Gant et al.			
	AF	6,699,854	03/02/2004	Wang et al.			
	AG	6,809,088	10/26/2004	Chabrier de Lassauniere et al.			
	AH	7,125,896	10/24/2006	Faull et al.			
	AI	7,166,639	01/23/2007	Wan et al.			
	AJ	7,358,376	04/15/2008	Baxter et al.			
	AK	US-2006-0111431	05/25/2006	Morley et al.			
	AL	US-2006-0058522	03/16/2006	Faull et al.			
	AM	US-2007-0015819	01/18/2007	Faull et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AN	EP 0202538	11/26/1986	EP			English Abstract attached	
	AO	EP 0853083	07/15/1998	EP				
	AP	EP 0908456	04/14/1999	EP			English Abstract attached	
	AQ	GB 1468012	03/23/1977	United Kingdom				
	AR	GB 2195634	04/13/1988	United Kingdom				
	AS	WO 98/02430	01/22/1998	WIPO				
	AT	WO 98/54116	12/03/1998	WIPO				
	AU	WO 99/46244	09/16/1999	WIPO				
	AV	WO 00/71532	11/30/2000	WIPO				
	AW	WO 01/58890	08/16/2001	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0460US1	Application No. 10/542,044
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew David Morley et al.	
		Filing Date July 13, 2005	Group Art Unit 1626

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AX	WO 01/98290	12/27/2001	WIPO				
	AY	WO 02/30353	04/18/2002	WIPO				
	AZ	WO 03/010158	02/06/2003	WIPO				
	AAA	WO 03/010163	02/06/2003	WIPO				
	ABB	WO 03/029241	04/10/2003	WIPO				
	ACC	WO 03/028731	04/10/2003	WIPO				
	ADD	WO 2004/063185	07/29/2004	WIPO				
	AEE	WO 2004/063186	07/29/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AFF	Awada et al., "The pipeline of new anticancer agents for breast cancer treatment in 2003", <i>Critical Reviews in Oncology/Hematology</i> 48:45-63 (2003)
	AGG	Berkow et al., The Merck Manual of Diagnosis and Therapy, 16 th Edition, © 1992, Merck Research Laboratories, Rahway, NJ, pages 1488 and 2664
	AHH	Chen et al., "TNF-R1 Signaling: A Beautiful Pathway", <i>Science</i> 296:1634-1635 (2002)
	AII	Compston et al., "Multiple sclerosis", <i>The Lancet</i> 359:1221-1231 (2002)
	AJJ	Du et al., "Aryl ureas represent a new class of anti-trypanosomal agents", <i>Chemistry & Biology</i> 7:733-742 (2000)
	AKK	Hartung et al., "What do we know about the mechanism of action of disease-modifying treatments in MS?" <i>J Neurol</i> 251(Suppl. 5):V/12-V/29 (2004)
	ALL	Karin et al., "NF- κ B in cancer: from innocent bystander to major culprit", <i>Nat. Rev. Cancer</i> 2:301-310 (2002)
	AMM	Luo et al., "IKK/NF- κ B signaling: balancing life and death – a new approach to cancer therapy", <i>J. Clin. Invest.</i> 115(10):2625-2632 (2005)
	ANN	Orlowski, et al., "NF- κ B as a therapeutic target in cancer", <i>TRENDS in Molecular Medicine</i> 8(8):385-389 (2002)
	AOO	Zayed et al., "Studies on 5-aminopyrazole derivatives. Synthesis of some new fused pyrazole derivatives", <i>Monatsh. Chem.</i> 115:431-436 (1984)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	